{ "nodes": [ [ "Migraine Disorders", "DISEASE" ], [ "Headache", "DISEASE" ], [ "Receptors, Calcitonin Gene-Related Peptide", "GENE" ], [ "Diarrhea", "DISEASE" ], [ "Transformed migraine", "DISEASE" ], [ "fremanezumab", "DRUG" ], [ "JP", "GENE" ], [ "Botulinum Toxins, Type A", "GENE" ], [ "Muscle Spasticity", "DISEASE" ], [ "calcitonin gene-related peptide", "GENE" ], [ "Nasopharyngitis", "DISEASE" ], [ "Episodic migraine", "DISEASE" ], [ "CGRP", "GENE" ], [ "Overactive Bladder", "DISEASE" ] ], "edges": [ [ [ "Receptors, Calcitonin Gene-Related Peptide", "Episodic migraine" ], 25.481278, [ [ "Jessica Ailani, Anjana Lalla, Rashmi B Halker Singh, Dagny Holle-Lee, Krisztian Nagy, Kari Kelton, Cristiano Piron, Pranav Gandhi, Patricia Pozo-Rosich (2024). Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies. Cephalalgia : an international journal of headache, 3331024241299377. https://doi.org/10.1177/03331024241299377 PMID: 39558612", "39558612" ], [ "Anjaneya Shankar Madhav Bandatmakur, Pooja Dave, Melissa Kerr, Colin Brunick, Sijin Wen, Nicholas Hansen (2024). Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA. Brain sciences. https://doi.org/10.3390/brainsci14090879 PMID: 39335375", "39335375" ], [ "Sarah Stuart, Stephanie Gregg, Sally Ware, Prut Koonalintip, Benjamin R Wakerley (2024). Patient-completed online \"follow-up form\" to assess continuation of anti-CGRP(r) antibody therapy in patients with chronic migraine: A pilot project. Clinical neurology and neurosurgery, 108594. https://doi.org/10.1016/j.clineuro.2024.108594 PMID: 39481344", "39481344" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ], [ "Sawsan Alabbad, Nathalia Figueredo, Hsiangkuo Yuan, Stephen Silberstein (2024). Developments in targeting calcitonin gene-related peptide. Expert review of neurotherapeutics, 477-485. https://doi.org/10.1080/14737175.2024.2332754 PMID: 38557226", "38557226" ], [ "Renato Oliveira, Raquel Gil-Gouveia, Francesca Puledda (2024). CGRP-targeted medication in chronic migraine - systematic review. The journal of headache and pain, 51. https://doi.org/10.1186/s10194-024-01753-y PMID: 38575868", "38575868" ], [ "Abdulrahim Saleh Alrasheed, Taif Mansour Almaqboul, Reem Ali Alshamrani, Noor Mohammad AlMohish, Majed Mohammad Alabdali (2024). Safety and Efficacy of Atogepant for the Preventive Treatment of Migraines in Adults: A Systematic Review and Meta-Analysis. Journal of clinical medicine. https://doi.org/10.3390/jcm13226713 PMID: 39597856", "39597856" ], [ "Jessica Ailani, Richard B Lipton, Andrew M Blumenfeld, Laszlo Mechtler, Brad C Klein, Molly Yizeng He, Jonathan H Smith, Joel M Trugman, Rosa de Abreu Ferreira, Elimor Brand-Schieber (2024). Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study. Headache. https://doi.org/10.1111/head.14871 PMID: 39569702", "39569702" ], [ "Selia Chowdhury, Tirth Dave (2023). Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine. Discoveries (Craiova, Romania), e167. https://doi.org/10.15190/d.2023.6 PMID: 37564925", "37564925" ], [ "Sena Uzun, Ulf Frejvall, Gülsen Özkaya-Sahin, Gürdal Sahin (2023). A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy? Frontiers in neurology, 1176816. https://doi.org/10.3389/fneur.2023.1176816 PMID: 37213912", "37213912" ] ] ], [ [ "Botulinum Toxins, Type A", "Headache" ], 9.8873135, [ [ "Agustin Melo-Carrillo, Andrew M Strassman, Khrystoffer-Kihan J Malcolm, Aubrey Manack Adams, Brett Dabruzzo, Ron S Briode, Mitchell F Brin, Rami Burstein (2024). Exploring the effects of extracranial injections of botulinum toxin type A on activation and sensitization of central trigeminovascular neurons by cortical spreading depression in male and female rats. Cephalalgia : an international journal of headache, 3331024241278919. https://doi.org/10.1177/03331024241278919 PMID: 39252510", "39252510" ], [ "Fatemeh Farham, Dilara Onan, Paolo Martelletti (2024). Non-Migraine Head Pain and Botulinum Toxin. Toxins. https://doi.org/10.3390/toxins16100431 PMID: 39453207", "39453207" ], [ "Grace Forde, Benjamin M Brucker, Kimberly Becker Ifantides, Atul T Patel, Angeli Mayadev, Theodore Brown, Ziyad Ayyoub, Kenneth Martinez, Ritu Singh, Mariana Nelson, Simona Battucci, Irina Yushmanova, Ahunna Ukah, Christopher Rhyne (2024). SYNCHRONIZE: Real-World Retrospective Safety Analysis of Patients Treated with OnabotulinumtoxinA for More than One Therapeutic Indication. Toxins. https://doi.org/10.3390/toxins16100420 PMID: 39453196", "39453196" ], [ "Alex Jaimes, Andrea Gómez, Olga Pajares, Jaime Rodríguez-Vico (2024). OnabotulinumtoxinA as a promising treatment for primary trochlear headache: A retrospective case series. Headache, 589-594. https://doi.org/10.1111/head.14699 PMID: 38533675", "38533675" ], [ "Matthew Robbins (2024). New Daily Persistent Headache. Continuum (Minneapolis, Minn.), 425-437. https://doi.org/10.1212/CON.0000000000001398 PMID: 38568492", "38568492" ], [ "Hema Mistry, Seyran Naghdi, Anna Brown, Sophie Rees, Jason Madan, Amy Grove, Saval Khanal, Callum Duncan, Manjit Matharu, Andrew Cooklin, Aiva Aksentyte, Natasha Davies, Martin Underwood (2024). Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling. Health technology assessment (Winchester, England), 1-329. https://doi.org/10.3310/AYWA5297 PMID: 39365169", "39365169" ], [ "Seyran Naghdi, Martin Underwood, Anna Brown, Manjit Matharu, Callum Duncan, Natasha Davies, Aiva Aksentyte, Hema Mistry (2024). Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review. BMJ neurology open, e000616. https://doi.org/10.1136/bmjno-2023-000616 PMID: 38646505", "38646505" ], [ "Fanyi Kong, Dawn C Buse, Guoliang Zhu, Jingjing Xu (2024). Comparative efficacy and safety of different pharmacological therapies to medication overuse headache: a network meta-analysis. The journal of headache and pain, 168. https://doi.org/10.1186/s10194-024-01878-0 PMID: 39375607", "39375607" ], [ "Richard N Miller, Monica E Kim, Muhammed Talha Gunduz, Shawn C Aylward (2024). Advancements in pediatric headache. Current opinion in pediatrics, 624-629. https://doi.org/10.1097/MOP.0000000000001412 PMID: 39400079", "39400079" ], [ "Marvin Thepsoparn, Prakit Anukoolwittaya, Patcharapol Toeypromthong, Chanon Thanaboriboon (2024). Efficacy and safety profile of Onabotulinum toxin-A injection at sphenopalatine ganglion in trigeminal neuralgia: a prospective observational study. The journal of headache and pain, 210. https://doi.org/10.1186/s10194-024-01926-9 PMID: 39623300", "39623300" ] ] ], [ [ "CGRP", "Headache" ], 41.509576, [ [ "E Pons-Fuster, O Lozano-Caballero, S Martín-Balbuena, C Lucas-Ródenas, A Mancebo-González, I De Gorostiza-Frías, C M González-Ponce (2024). Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. International journal of clinical pharmacy, 1317-1326. https://doi.org/10.1007/s11096-024-01758-2 PMID: 38990457", "38990457" ], [ "Lanfranco Pellesi, Messoud Ashina, Paolo Martelletti (2024). Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. Expert opinion on emerging drugs, 57-64. https://doi.org/10.1080/14728214.2024.2317778 PMID: 38337150", "38337150" ], [ "Marta Pascual-Mato, Gabriel Gárate, Vicente González-Quintanilla, Jorge Madera-Fernández, Beatriz Castro, María José García, Javier Crespo, Montserrat Rivero, Julio Pascual (2024). Differences in circulating alpha-calcitonin gene-related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross-sectional study. Headache, 849-858. https://doi.org/10.1111/head.14768 PMID: 38922858", "38922858" ], [ "Fatemeh Farham, Dilara Onan, Paolo Martelletti (2024). Non-Migraine Head Pain and Botulinum Toxin. Toxins. https://doi.org/10.3390/toxins16100431 PMID: 39453207", "39453207" ], [ "Xiaoxin Wang, Yan Sun, Yuan Zhang, Zhaohui Zhi, Shilin Wang, Jiaohui Li, Yingzhe Sun, Yuanzheng Sun (2024). Research trends and hotspots in clinical trials of migraine in the past 20 years: bibliometric analysis. Frontiers in neurology, 1430138. https://doi.org/10.3389/fneur.2024.1430138 PMID: 39524909", "39524909" ], [ "Nazia Karsan, Lars Edvinsson, Laszlo Vecsei, Peter J Goadsby (2024). Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders. Annals of clinical and translational neurology, 1654-1668. https://doi.org/10.1002/acn3.52119 PMID: 38887982", "38887982" ], [ "Prakit Anukoolwittaya, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Wanakorn Rattanawong (2024). Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand. The journal of headache and pain, 150. https://doi.org/10.1186/s10194-024-01859-3 PMID: 39267011", "39267011" ], [ "Pablo Irimia, Sonia Santos-Lasaosa, Patricia Pozo-Rosich, Rogelio Leira, Julio Pascual, José Miguel Láinez (2024). Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. Frontiers in neurology, 1355877. https://doi.org/10.3389/fneur.2024.1355877 PMID: 38523607", "38523607" ], [ "Seyran Naghdi, Martin Underwood, Anna Brown, Manjit Matharu, Callum Duncan, Natasha Davies, Aiva Aksentyte, Hema Mistry (2024). Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review. BMJ neurology open, e000616. https://doi.org/10.1136/bmjno-2023-000616 PMID: 38646505", "38646505" ], [ "Teddy Hervias (2024). An update on migraine: Current and new treatment options. JAAPA : official journal of the American Academy of Physician Assistants, 1-7. https://doi.org/10.1097/01.JAA.0000000000000014 PMID: 38662902", "38662902" ] ] ], [ [ "fremanezumab", "CGRP" ], 25.654718, [ [ "Anna Maria Florescu, Lærke Vig Lannov, Samaira Younis, Christopher Kjaer Cullum, Basit Ali Chaudhry, Thien Phu Do, Faisal Mohammad Amin (2024). No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study. Cephalalgia : an international journal of headache, 3331024231222915. https://doi.org/10.1177/03331024231222915 PMID: 38215232", "38215232" ], [ "Oralee J Varnado, Brenna L Brady, Anthony J Zagar, Yvonne P Robles, Margaret Hoyt (2024). Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study. Patient preference and adherence, 69-88. https://doi.org/10.2147/PPA.S437396 PMID: 38223442", "38223442" ], [ "Mark Esguerra, Emily Rubenstein Engel (2024). Fremanezumab-associated injection site alopecia. BMJ case reports. https://doi.org/10.1136/bcr-2024-260741 PMID: 39134332", "39134332" ], [ "E Pons-Fuster, O Lozano-Caballero, S Martín-Balbuena, C Lucas-Ródenas, A Mancebo-González, I De Gorostiza-Frías, C M González-Ponce (2024). Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. International journal of clinical pharmacy, 1317-1326. https://doi.org/10.1007/s11096-024-01758-2 PMID: 38990457", "38990457" ], [ "Elena Cresta, Alessia Bellotti, Giovanni Rinaldi, Ilenia Corbelli, Paola Sarchielli (2024). Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study. CNS neuroscience & therapeutics, e14595. https://doi.org/10.1111/cns.14595 PMID: 38332541", "38332541" ], [ "Marta Waliszewska-Prosół, Paolo Martelletti (2024). Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway. Dental and medical problems, 9-11. https://doi.org/10.17219/dmp/174706 PMID: 38284301", "38284301" ], [ "Davide Mascarella, Giorgia Andrini, Carlo Baraldi, Claudia Altamura, Valentina Favoni, Flavia Lo Castro, Giulia Pierangeli, Fabrizio Vernieri, Simona Guerzoni, Sabina Cevoli (2024). Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 5365-5373. https://doi.org/10.1007/s10072-024-07567-9 PMID: 38795273", "38795273" ], [ "Lanfranco Pellesi, Dilara Onan, Paolo Martelletti (2024). Onabotulinumtoxin A for the Treatment of Post-Traumatic Headache: Is It Better than Anti-CGRP Antibodies? Toxins. https://doi.org/10.3390/toxins16100427 PMID: 39453203", "39453203" ], [ "Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, Giulia Fiorentini, Piero Barbanti (2024). Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence. Brain sciences. https://doi.org/10.3390/brainsci14090948 PMID: 39335442", "39335442" ], [ "Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia : an international journal of headache, 3331024241238153. https://doi.org/10.1177/03331024241238153 PMID: 38477313", "38477313" ] ] ], [ [ "fremanezumab", "calcitonin gene-related peptide" ], 18.589551999999998, [ [ "Oralee J Varnado, Brenna L Brady, Anthony J Zagar, Yvonne P Robles, Margaret Hoyt (2024). Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study. Patient preference and adherence, 69-88. https://doi.org/10.2147/PPA.S437396 PMID: 38223442", "38223442" ], [ "Mark Esguerra, Emily Rubenstein Engel (2024). Fremanezumab-associated injection site alopecia. BMJ case reports. https://doi.org/10.1136/bcr-2024-260741 PMID: 39134332", "39134332" ], [ "E Pons-Fuster, O Lozano-Caballero, S Martín-Balbuena, C Lucas-Ródenas, A Mancebo-González, I De Gorostiza-Frías, C M González-Ponce (2024). Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. International journal of clinical pharmacy, 1317-1326. https://doi.org/10.1007/s11096-024-01758-2 PMID: 38990457", "38990457" ], [ "Elena Cresta, Alessia Bellotti, Giovanni Rinaldi, Ilenia Corbelli, Paola Sarchielli (2024). Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study. CNS neuroscience & therapeutics, e14595. https://doi.org/10.1111/cns.14595 PMID: 38332541", "38332541" ], [ "Marta Waliszewska-Prosół, Paolo Martelletti (2024). Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway. Dental and medical problems, 9-11. https://doi.org/10.17219/dmp/174706 PMID: 38284301", "38284301" ], [ "Davide Mascarella, Giorgia Andrini, Carlo Baraldi, Claudia Altamura, Valentina Favoni, Flavia Lo Castro, Giulia Pierangeli, Fabrizio Vernieri, Simona Guerzoni, Sabina Cevoli (2024). Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 5365-5373. https://doi.org/10.1007/s10072-024-07567-9 PMID: 38795273", "38795273" ], [ "Lanfranco Pellesi, Dilara Onan, Paolo Martelletti (2024). Onabotulinumtoxin A for the Treatment of Post-Traumatic Headache: Is It Better than Anti-CGRP Antibodies? Toxins. https://doi.org/10.3390/toxins16100427 PMID: 39453203", "39453203" ], [ "Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, Giulia Fiorentini, Piero Barbanti (2024). Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence. Brain sciences. https://doi.org/10.3390/brainsci14090948 PMID: 39335442", "39335442" ], [ "Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia : an international journal of headache, 3331024241238153. https://doi.org/10.1177/03331024241238153 PMID: 38477313", "38477313" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ] ] ], [ [ "fremanezumab", "Migraine Disorders" ], 137.772, [ [ "Anna Maria Florescu, Lærke Vig Lannov, Samaira Younis, Christopher Kjaer Cullum, Basit Ali Chaudhry, Thien Phu Do, Faisal Mohammad Amin (2024). No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study. Cephalalgia : an international journal of headache, 3331024231222915. https://doi.org/10.1177/03331024231222915 PMID: 38215232", "38215232" ], [ "Oralee J Varnado, Brenna L Brady, Anthony J Zagar, Yvonne P Robles, Margaret Hoyt (2024). Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study. Patient preference and adherence, 69-88. https://doi.org/10.2147/PPA.S437396 PMID: 38223442", "38223442" ], [ "E Pons-Fuster, O Lozano-Caballero, S Martín-Balbuena, C Lucas-Ródenas, A Mancebo-González, I De Gorostiza-Frías, C M González-Ponce (2024). Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. International journal of clinical pharmacy, 1317-1326. https://doi.org/10.1007/s11096-024-01758-2 PMID: 38990457", "38990457" ], [ "Lanfranco Pellesi, Dilara Onan, Paolo Martelletti (2024). Onabotulinumtoxin A for the Treatment of Post-Traumatic Headache: Is It Better than Anti-CGRP Antibodies? Toxins. https://doi.org/10.3390/toxins16100427 PMID: 39453203", "39453203" ], [ "Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, Giulia Fiorentini, Piero Barbanti (2024). Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence. Brain sciences. https://doi.org/10.3390/brainsci14090948 PMID: 39335442", "39335442" ], [ "Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia : an international journal of headache, 3331024241238153. https://doi.org/10.1177/03331024241238153 PMID: 38477313", "38477313" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ], [ "Hema Mistry, Seyran Naghdi, Anna Brown, Sophie Rees, Jason Madan, Amy Grove, Saval Khanal, Callum Duncan, Manjit Matharu, Andrew Cooklin, Aiva Aksentyte, Natasha Davies, Martin Underwood (2024). Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling. Health technology assessment (Winchester, England), 1-329. https://doi.org/10.3310/AYWA5297 PMID: 39365169", "39365169" ], [ "Carlos Lazaro-Hernandez, Edoardo Caronna, Joana Rosell-Mirmi, Victor J Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich (2024). Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population. The journal of headache and pain, 21. https://doi.org/10.1186/s10194-024-01727-0 PMID: 38347485", "38347485" ], [ "Seyran Naghdi, Martin Underwood, Anna Brown, Manjit Matharu, Callum Duncan, Natasha Davies, Aiva Aksentyte, Hema Mistry (2024). Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review. BMJ neurology open, e000616. https://doi.org/10.1136/bmjno-2023-000616 PMID: 38646505", "38646505" ] ] ], [ [ "fremanezumab", "Headache" ], 37.731359999999995, [ [ "Andreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, Dimitrios Rikos, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos, Anna P Andreou, Michail Vikelis (2024). Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry. Expert review of neurotherapeutics, 1119-1126. https://doi.org/10.1080/14737175.2024.2403576 PMID: 39279446", "39279446" ], [ "Anna Maria Florescu, Lærke Vig Lannov, Samaira Younis, Christopher Kjaer Cullum, Basit Ali Chaudhry, Thien Phu Do, Faisal Mohammad Amin (2024). No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study. Cephalalgia : an international journal of headache, 3331024231222915. https://doi.org/10.1177/03331024231222915 PMID: 38215232", "38215232" ], [ "Jason Charles Ray, Linda Dalic, Josephine Baker, Shuli Cheng, Elspeth Jane Hutton, Manjit Matharu (2024). Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study. BMJ neurology open, e000547. https://doi.org/10.1136/bmjno-2023-000547 PMID: 38268750", "38268750" ], [ "Shoji Kikui, Danno Daisuke, Junichi Miyahara, Hanako Sugiyama, Kuniko Ota, Kenji Murakata, Yoshihiro Kashiwaya, Takao Takeshima (2024). Effectiveness of fremanezumab treatment in patients with migraine headache. Pain medicine (Malden, Mass.), 664-670. https://doi.org/10.1093/pm/pnae050 PMID: 38889289", "38889289" ], [ "Mark Esguerra, Emily Rubenstein Engel (2024). Fremanezumab-associated injection site alopecia. BMJ case reports. https://doi.org/10.1136/bcr-2024-260741 PMID: 39134332", "39134332" ], [ "E Pons-Fuster, O Lozano-Caballero, S Martín-Balbuena, C Lucas-Ródenas, A Mancebo-González, I De Gorostiza-Frías, C M González-Ponce (2024). Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. International journal of clinical pharmacy, 1317-1326. https://doi.org/10.1007/s11096-024-01758-2 PMID: 38990457", "38990457" ], [ "Elena Cresta, Alessia Bellotti, Giovanni Rinaldi, Ilenia Corbelli, Paola Sarchielli (2024). Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study. CNS neuroscience & therapeutics, e14595. https://doi.org/10.1111/cns.14595 PMID: 38332541", "38332541" ], [ "Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, Mattia Canella, Marilena Marcosano, Claudia Altamura, Fabrizio Vernieri (2024). Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. The journal of headache and pain, 14. https://doi.org/10.1186/s10194-024-01721-6 PMID: 38308209", "38308209" ], [ "Emmanouil V Dermitzakis, Andreas A Argyriou, Konstantinos Bilias, Evangelia Barmpa, Sofia Liapi, Dimitrios Rikos, Georgia Xiromerisiou, Panagiotis Soldatos, Michail Vikelis (2024). Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options. Journal of clinical medicine. https://doi.org/10.3390/jcm13102768 PMID: 38792309", "38792309" ], [ "Muneto Tatsumoto, Miki Ishida, Katsuhiro Iba, Byung-Kun Kim, Xiaoping Ning, Chihiro Osawa, Masami Nakai, Yuka Kurita (2024). Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial. Headache. https://doi.org/10.1111/head.14810 PMID: 39221611", "39221611" ] ] ], [ [ "Botulinum Toxins, Type A", "Muscle Spasticity" ], 14.233229999999999, [ [ "Osman Boyalı, Serdar Kabatas, Erdinç Civelek, Omer Ozdemir, Yeliz Bahar-Ozdemir, Necati Kaplan, Eyüp Can Savrunlu, Erdal Karaöz (2024). Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy. World journal of clinical cases, 1585-1596. https://doi.org/10.12998/wjcc.v12.i9.1585 PMID: 38576742", "38576742" ], [ "Grace Forde, Benjamin M Brucker, Kimberly Becker Ifantides, Atul T Patel, Angeli Mayadev, Theodore Brown, Ziyad Ayyoub, Kenneth Martinez, Ritu Singh, Mariana Nelson, Simona Battucci, Irina Yushmanova, Ahunna Ukah, Christopher Rhyne (2024). SYNCHRONIZE: Real-World Retrospective Safety Analysis of Patients Treated with OnabotulinumtoxinA for More than One Therapeutic Indication. Toxins. https://doi.org/10.3390/toxins16100420 PMID: 39453196", "39453196" ], [ "Panfeng Jin, Yiwen Wang (2024). The Impact of Botulinum Toxin Combined with Robot-Assisted Gait Training on Spasticity and Gross Motor Function on Children with Spastic Cerebral Palsy. Developmental neurorehabilitation, 155-160. https://doi.org/10.1080/17518423.2024.2365801 PMID: 38867662", "38867662" ], [ "E V Kostenko (2023). [The use of botulinum toxin type A in symptomatic therapy and medical rehabilitation of patients with multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 17-25. https://doi.org/10.17116/jnevro202312310117 PMID: 37966435", "37966435" ], [ "Tomáš Veverka, Pavel Hok, Markéta Trnečková, Pavel Otruba, Jana Zapletalová, Zbyněk Tüdös, Martin Lotze, Petr Kaňovský, Petr Hluštík (2023). Interhemispheric parietal cortex connectivity reflects improvement in post-stroke spasticity due to treatment with botulinum toxin-A. Journal of the neurological sciences, 120588. https://doi.org/10.1016/j.jns.2023.120588 PMID: 36827809", "36827809" ], [ "Céline Klein, Richard Gouron, Vincent Barbier (2023). Effects of botulinum toxin injections in the upper limbs of children with cerebral palsy: A systematic review of the literature. Orthopaedics & traumatology, surgery & research : OTSR, 103578. https://doi.org/10.1016/j.otsr.2023.103578 PMID: 36754169", "36754169" ], [ "Michaela Bonfert, Florian Heinen, Petr Kaňovský, A Sebastian Schroeder, Henry G Chambers, Edward Dabrowski, Thorin L Geister, Angelika Hanschmann, Michael Althaus, Marta Banach, Deborah Gaebler-Spira (2023). Spasticity-related pain in children/adolescents with cerebral palsy. Part 2: IncobotulinumtoxinA efficacy results from a pooled analysis. Journal of pediatric rehabilitation medicine, 83-98. https://doi.org/10.3233/PRM-220020 PMID: 36057802", "36057802" ], [ "Kardelen Gencer Atalay, Evrim Karadag Saygi, Firat Akbas, Ozge Kenis Coskun, Ahmet Hamdi Akgulle, Ilker Yagci (2022). Does ultrasound imaging of the spastic muscle have an additive effect on clinical examination tools in patients with cerebral palsy?: A pilot study. Northern clinics of Istanbul, 102-108. https://doi.org/10.14744/10.14744/nci.2020.78045 PMID: 35582513", "35582513" ], [ "Klemens Fheodoroff, Astrid Scheschonka, Jörg Wissel (2022). Goal analysis in patients with limb spasticity treated with incobotulinumtoxinA in the TOWER study. Disability and rehabilitation, 1367-1373. https://doi.org/10.1080/09638288.2020.1804627 PMID: 32805151", "32805151" ], [ "Shannon Y Chiu, Matthew R Burns, Irene A Malaty (2021). An Update on Botulinum Toxin in Neurology. Neurologic clinics, 209-229. https://doi.org/10.1016/j.ncl.2020.09.014 PMID: 33223084", "33223084" ] ] ], [ [ "JP", "Diarrhea" ], 29.188601000000002, [ [ "Nian Liu, Jilei Li, Yichong Wang, Shengsheng Zhang (2023). Different therapies of Chinese herbal medicine for diarrhea-predominant irritable bowel syndrome: A network meta-analysis of double-blinded, placebo-controlled trials. Journal of ethnopharmacology, 116672. https://doi.org/10.1016/j.jep.2023.116672 PMID: 37328079", "37328079" ], [ "Maika Kudoh, Toshihiko Kakiuchi, Masato Yoshiura, Motohiro Esaki, Muneaki Matsuo (2023). Fecal calprotectin measurement to detect recurrence of solitary juvenile polyps: A case report. Medicine, e35448. https://doi.org/10.1097/MD.0000000000035448 PMID: 37904372", "37904372" ], [ "Chihiro Kosugi, Keiji Koda, Tadamichi Denda, Keiichiro Ishibashi, Hideyuki Ishida, Kazuhiro Seike, Haruhito Sakata, Shinji Yanagisawa, Akinari Miyazaki, Wataru Takayama, Naoto Koike, Hiroaki Shimizu, Hisahiro Matsubara (2021). Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial). International journal of colorectal disease, 2637-2647. https://doi.org/10.1007/s00384-021-03995-7 PMID: 34368890", "34368890" ], [ "Makoto Tahara, Naomi Kiyota, Ken-Ichi Nibu, Ayumi Akamatsu, Tomohiro Hoshino, Ryuichi Hayashi (2021). Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance. International journal of clinical oncology, 1619-1627. https://doi.org/10.1007/s10147-021-01949-1 PMID: 34110532", "34110532" ], [ "Nobuyuki Yamamoto, Yoichi Nakanishi, Akihiko Gemma, Kazuhiko Nakagawa, Takahiko Sakamoto, Ayumi Akamatsu, Yuichiro Ohe (2021). Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance. Cancer science, 4692-4701. https://doi.org/10.1111/cas.15117 PMID: 34431585", "34431585" ], [ "Toshihisa Takeuchi, Takahisa Furuta, Yasuhiro Fujiwara, Mitsushige Sugimoto, Kunio Kasugai, Motoyasu Kusano, Hiroyuki Okada, Takahiro Suzuki, Tomohiro Higuchi, Takuma Kagami, Takahiro Uotani, Mihoko Yamade, Akinari Sawada, Fumio Tanaka, Satoshi Harada, Kazuhiro Ota, Yuichi Kojima, Masaki Murata, Yasuhiro Tamura, Yasushi Funaki, Osamu Kawamura, Yuki Okamoto, Kazuma Fujimoto, Kazuhide Higuchi (2020). Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Alimentary pharmacology & therapeutics, 534-543. https://doi.org/10.1111/apt.15641 PMID: 31990424", "31990424" ], [ "Toshihiro Kudo, Yasuo Hamamoto, Ken Kato, Takashi Ura, Takashi Kojima, Takahiro Tsushima, Shuichi Hironaka, Hiroki Hara, Taroh Satoh, Satoru Iwasa, Kei Muro, Hirofumi Yasui, Keiko Minashi, Kensei Yamaguchi, Atsushi Ohtsu, Yuichiro Doki, Yuko Kitagawa (2017). Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. The Lancet. Oncology, 631-639. https://doi.org/10.1016/S1470-2045(17)30181-X PMID: 28314688", "28314688" ], [ "Kazufumi Nakamura, Hiroki Oe, Hajime Kihara, Kenei Shimada, Shota Fukuda, Kyoko Watanabe, Tsutomu Takagi, Kei Yunoki, Toru Miyoshi, Kumiko Hirata, Junichi Yoshikawa, Hiroshi Ito (2014). DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovascular diabetology, 110. https://doi.org/10.1186/s12933-014-0110-2 PMID: 25074318", "25074318" ], [ "Li-li Deng, Wei Liu, Dong-mei Tan (2010). [Norovrius genotype I.8 being detected from sporadic cases of acute gastroenteritis in Nanning municipal]. Zhongguo yi miao he mian yi, 241-5. PMID: 20726267", "20726267" ], [ "Mukti Kant Nayak, Debarati Chatterjee, S M Nataraju, Madhusudan Pativada, Utpala Mitra, Mrinal Kanti Chatterjee, Tushar K Saha, U Sarkar, Triveni Krishnan (2009). A new variant of Norovirus GII.4/2007 and inter-genotype recombinant strains of NVGII causing acute watery diarrhoea among children in Kolkata, India. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 223-9. https://doi.org/10.1016/j.jcv.2009.04.018 PMID: 19464942", "19464942" ] ] ], [ [ "calcitonin gene-related peptide", "Migraine Disorders" ], 55.084740000000004, [ [ "Lauren Powell, Fiona O'Sullivan, Pramoda Jayasinghe, Basia Rogula, Feng Dai, Jessica Cirillo, Samantha Sweeney, Lucy Abraham, Jessica Ailani (2025). Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial. The journal of headache and pain, 1. https://doi.org/10.1186/s10194-024-01915-y PMID: 39748312", "39748312" ], [ "Guy Greco, Teshamae Monteith (2024). Intranasal zavegepant for the acute treatment of migraine. Expert review of neurotherapeutics, 1131-1140. https://doi.org/10.1080/14737175.2024.2405741 PMID: 39314003", "39314003" ], [ "Davide Para, Chiara Camponovo, Gianna Carla Riccitelli, Giulia Mallucci, Paolo Maino, Camilla Mondini Trissino da Lodi, Demurtas Saudina, Pierpaolo Trimboli, Claudio Gobbi, Chiara Zecca (2024). Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies. CNS drugs, 819-825. https://doi.org/10.1007/s40263-024-01104-0 PMID: 39174745", "39174745" ], [ "Yao Zhang, Fei Ge, Yamin Luo, Xuenian Ji, Zijian Liu, Yuehua Qiu, Jianchen Hou, Ranran Zhou, Caihong Zhao, Qianwei Xu, Shujing Zhang, Xue Yu, Chunguo Wang, Dongyu Ge, Fengxian Meng, Xiaohua Tao (2024). Paeonol and glycyrrhizic acid in combination ameliorate the recurrent nitroglycerin-induced migraine-like phenotype in rats by regulating the GABBR2/TRPM8/PRKACA/TRPV1 pathway. Journal of ethnopharmacology, 118464. https://doi.org/10.1016/j.jep.2024.118464 PMID: 38908492", "38908492" ], [ "E Pons-Fuster, O Lozano-Caballero, S Martín-Balbuena, C Lucas-Ródenas, A Mancebo-González, I De Gorostiza-Frías, C M González-Ponce (2024). Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. International journal of clinical pharmacy, 1317-1326. https://doi.org/10.1007/s11096-024-01758-2 PMID: 38990457", "38990457" ], [ "Richard B Lipton, Stephanie J Nahas, Patricia Pozo-Rosich, Tanya Bilchik, Peter McAllister, Michelle Finnegan, Yingyi Liu, Natty Chalermpalanupap, Brett Dabruzzo, David W Dodick (2024). Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. The journal of headache and pain, 83. https://doi.org/10.1186/s10194-024-01783-6 PMID: 38773375", "38773375" ], [ "Lanfranco Pellesi, Dilara Onan, Paolo Martelletti (2024). Onabotulinumtoxin A for the Treatment of Post-Traumatic Headache: Is It Better than Anti-CGRP Antibodies? Toxins. https://doi.org/10.3390/toxins16100427 PMID: 39453203", "39453203" ], [ "Matthew Robbins (2024). New Daily Persistent Headache. Continuum (Minneapolis, Minn.), 425-437. https://doi.org/10.1212/CON.0000000000001398 PMID: 38568492", "38568492" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ], [ "Nazia Karsan (2024). Pathophysiology of Migraine. Continuum (Minneapolis, Minn.), 325-343. https://doi.org/10.1212/CON.0000000000001412 PMID: 38568486", "38568486" ] ] ], [ [ "fremanezumab", "Botulinum Toxins, Type A" ], 9.951, [ [ "Chia-Chun Chiang, Todd J Schwedt, Gina Dumkrieger, Liguo Wang, Chieh-Ju Chao, Heather A Ouellette, Imon Banerjee, Yi-Chieh Chen, Brandon M Jones, Krista M Burke, Han Wang, Ann M Murray, Monique M Montenegro, Jennifer I Stern, Mark Whealy, Narayan Kissoon, Fred M Cutrer (2024). Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features. Headache, 1094-1108. https://doi.org/10.1111/head.14806 PMID: 39176658", "39176658" ], [ "Anjaneya Shankar Madhav Bandatmakur, Pooja Dave, Melissa Kerr, Colin Brunick, Sijin Wen, Nicholas Hansen (2024). Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA. Brain sciences. https://doi.org/10.3390/brainsci14090879 PMID: 39335375", "39335375" ], [ "Sharon Wolters, Johannes A Carpay, Marja H Pronk, Karin W M Zuurbier, Maurice T Driessen, Leonidas Lyras, Maarten J Postma (2024). A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy. BMC neurology, 214. https://doi.org/10.1186/s12883-024-03697-x PMID: 38914929", "38914929" ], [ "Seyran Naghdi, Martin Underwood, Anna Brown, Manjit Matharu, Callum Duncan, Natasha Davies, Aiva Aksentyte, Hema Mistry (2024). Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review. BMJ neurology open, e000616. https://doi.org/10.1136/bmjno-2023-000616 PMID: 38646505", "38646505" ], [ "Juan Tudela-Tomas, Rosa-Maria Ramos-Guerrero, Maria-Eugenia Rodriguez-Mateos (2024). Reversion of chronic to episodic migraine in working age and botulinum toxin-resistant patients treated with fremanezumab: A real-life study. Brain and behavior, e3631. https://doi.org/10.1002/brb3.3631 PMID: 39034358", "39034358" ], [ "Fanyi Kong, Dawn C Buse, Guoliang Zhu, Jingjing Xu (2024). Comparative efficacy and safety of different pharmacological therapies to medication overuse headache: a network meta-analysis. The journal of headache and pain, 168. https://doi.org/10.1186/s10194-024-01878-0 PMID: 39375607", "39375607" ], [ "Oralee J Varnado, Michelle Vu, Erin K Buysman, Gilwan Kim, Gayle Allenback, Margaret Hoyt, Helen Trenz, Feng Cao, Lars Viktrup (2024). Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study. Current medical research and opinion, 635-646. https://doi.org/10.1080/03007995.2024.2316864 PMID: 38334320", "38334320" ], [ "Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, Mattia Canella, Marilena Marcosano, Claudia Altamura, Fabrizio Vernieri (2024). Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. The journal of headache and pain, 14. https://doi.org/10.1186/s10194-024-01721-6 PMID: 38308209", "38308209" ], [ "Emmanouil V Dermitzakis, Andreas A Argyriou, Konstantinos Bilias, Evangelia Barmpa, Sofia Liapi, Dimitrios Rikos, Georgia Xiromerisiou, Panagiotis Soldatos, Michail Vikelis (2024). Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options. Journal of clinical medicine. https://doi.org/10.3390/jcm13102768 PMID: 38792309", "38792309" ], [ "Yen-Feng Wang, Fu-Chi Yang, Lu-An Chen, Ting-Yu Chang, Hui-Chen Su, Chun-Pai Yang, Yi-Hsien Tu, Yi-Shiang Tzeng, Shih-Pin Chen, Jong-Ling Fuh, Kuan-Lin Lai, Yu-Hsiang Ling, Wei-Ta Chen, Shuu-Jiun Wang (2024). Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan. European journal of neurology, e16372. https://doi.org/10.1111/ene.16372 PMID: 38837528", "38837528" ] ] ], [ [ "calcitonin gene-related peptide", "Headache" ], 40.281259999999996, [ [ "E Pons-Fuster, O Lozano-Caballero, S Martín-Balbuena, C Lucas-Ródenas, A Mancebo-González, I De Gorostiza-Frías, C M González-Ponce (2024). Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. International journal of clinical pharmacy, 1317-1326. https://doi.org/10.1007/s11096-024-01758-2 PMID: 38990457", "38990457" ], [ "Marta Pascual-Mato, Gabriel Gárate, Vicente González-Quintanilla, Jorge Madera-Fernández, Beatriz Castro, María José García, Javier Crespo, Montserrat Rivero, Julio Pascual (2024). Differences in circulating alpha-calcitonin gene-related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross-sectional study. Headache, 849-858. https://doi.org/10.1111/head.14768 PMID: 38922858", "38922858" ], [ "Matthew Robbins (2024). New Daily Persistent Headache. Continuum (Minneapolis, Minn.), 425-437. https://doi.org/10.1212/CON.0000000000001398 PMID: 38568492", "38568492" ], [ "Hema Mistry, Seyran Naghdi, Anna Brown, Sophie Rees, Jason Madan, Amy Grove, Saval Khanal, Callum Duncan, Manjit Matharu, Andrew Cooklin, Aiva Aksentyte, Natasha Davies, Martin Underwood (2024). Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling. Health technology assessment (Winchester, England), 1-329. https://doi.org/10.3310/AYWA5297 PMID: 39365169", "39365169" ], [ "Nazia Karsan (2024). Pathophysiology of Migraine. Continuum (Minneapolis, Minn.), 325-343. https://doi.org/10.1212/CON.0000000000001412 PMID: 38568486", "38568486" ], [ "Nazia Karsan, Lars Edvinsson, Laszlo Vecsei, Peter J Goadsby (2024). Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders. Annals of clinical and translational neurology, 1654-1668. https://doi.org/10.1002/acn3.52119 PMID: 38887982", "38887982" ], [ "Prakit Anukoolwittaya, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Wanakorn Rattanawong (2024). Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand. The journal of headache and pain, 150. https://doi.org/10.1186/s10194-024-01859-3 PMID: 39267011", "39267011" ], [ "Pablo Irimia, Sonia Santos-Lasaosa, Patricia Pozo-Rosich, Rogelio Leira, Julio Pascual, José Miguel Láinez (2024). Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. Frontiers in neurology, 1355877. https://doi.org/10.3389/fneur.2024.1355877 PMID: 38523607", "38523607" ], [ "Edoardo Caronna, Victor José Gallardo, Gabriella Egeo, Manuel Millán Vázquez, Candela Nieves Castellanos, Javier A Membrilla, Gloria Vaghi, Joana Rodríguez-Montolio, Neus Fabregat Fabra, Francisco Sánchez-Caballero, Alex Jaimes Sánchez, Albert Muñoz-Vendrell, Renato Oliveira, Gabriel Gárate, Yésica González-Osorio, Daniel Guisado-Alonso, Raffaele Ornello, Cem Thunstedt, Iris Fernández-Lázaro, Marta Torres-Ferrús, Alicia Alpuente, Paola Torelli, Cinzia Aurilia, Raquel Lamas Pére, Maria José Ruiz Castrillo, Roberto De Icco, Grazia Sances, Sarah Broadhurst, Hui Ching Ong, Andrea Gómez García, Sergio Campoy, Jordi Sanahuja, Gonçalo Cabral, Isabel Beltrán Blasco, Marta Waliszewska-Prosół, Liliana Pereira, Almudena Layos-Romero, Isabel Luzeiro, Laura Dorado, María Rocio Álvarez Escudero, Arne May, Alba López-Bravo, Isabel Pavão Martins, Christina Sundal, Pablo Irimia, Alberto Lozano Ros, Ana Beatriz Gago-Veiga, Fernando Velasco Juanes, Ruth Ruscheweyh, Simona Sacco, Elisa Cuadrado-Godia, David García-Azorín, Julio Pascual, Raquel Gil-Gouveia, Mariano Huerta-Villanueva, Jaime Rodriguez-Vico, Javier Viguera Romero, Victor Obach, Sonia Santos-Lasaosa, Mona Ghadiri-Sani, Cristina Tassorelli, Javier Díaz-de-Terán, Samuel Díaz Insa, Carmen González Oria, Piero Barbanti, Patricia Pozo-Rosich, (2024). Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. Journal of neurology, neurosurgery, and psychiatry, 927-937. https://doi.org/10.1136/jnnp-2023-333295 PMID: 38777579", "38777579" ], [ "Seyran Naghdi, Martin Underwood, Anna Brown, Manjit Matharu, Callum Duncan, Natasha Davies, Aiva Aksentyte, Hema Mistry (2024). Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review. BMJ neurology open, e000616. https://doi.org/10.1136/bmjno-2023-000616 PMID: 38646505", "38646505" ] ] ], [ [ "CGRP", "Transformed migraine" ], 20.695932, [ [ "Anna Maria Florescu, Lærke Vig Lannov, Samaira Younis, Christopher Kjaer Cullum, Basit Ali Chaudhry, Thien Phu Do, Faisal Mohammad Amin (2024). No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study. Cephalalgia : an international journal of headache, 3331024231222915. https://doi.org/10.1177/03331024231222915 PMID: 38215232", "38215232" ], [ "Kofi Frimpong-Manson, Yuma T Ortiz, Lance R McMahon, Jenny L Wilkerson (2024). Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics. Frontiers in molecular neuroscience, 1355281. https://doi.org/10.3389/fnmol.2024.1355281 PMID: 38481473", "38481473" ], [ "Yao Zhang, Fei Ge, Yamin Luo, Xuenian Ji, Zijian Liu, Yuehua Qiu, Jianchen Hou, Ranran Zhou, Caihong Zhao, Qianwei Xu, Shujing Zhang, Xue Yu, Chunguo Wang, Dongyu Ge, Fengxian Meng, Xiaohua Tao (2024). Paeonol and glycyrrhizic acid in combination ameliorate the recurrent nitroglycerin-induced migraine-like phenotype in rats by regulating the GABBR2/TRPM8/PRKACA/TRPV1 pathway. Journal of ethnopharmacology, 118464. https://doi.org/10.1016/j.jep.2024.118464 PMID: 38908492", "38908492" ], [ "Tianxiao Wang, Chenlu Zhu, Kaibo Zhang, Jinggui Gao, Yunhao Xu, Chenyang Duan, Shouyi Wu, Cheng Peng, Jisong Guan, Yonggang Wang (2024). Targeting IGF1/IGF1r signaling relieve pain and autophagic dysfunction in NTG-induced chronic migraine model of mice. The journal of headache and pain, 156. https://doi.org/10.1186/s10194-024-01864-6 PMID: 39304806", "39304806" ], [ "Marta Pascual-Mato, Gabriel Gárate, Vicente González-Quintanilla, Jorge Madera-Fernández, Beatriz Castro, María José García, Javier Crespo, Montserrat Rivero, Julio Pascual (2024). Differences in circulating alpha-calcitonin gene-related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross-sectional study. Headache, 849-858. https://doi.org/10.1111/head.14768 PMID: 38922858", "38922858" ], [ "Lanfranco Pellesi, Dilara Onan, Paolo Martelletti (2024). Onabotulinumtoxin A for the Treatment of Post-Traumatic Headache: Is It Better than Anti-CGRP Antibodies? Toxins. https://doi.org/10.3390/toxins16100427 PMID: 39453203", "39453203" ], [ "Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia : an international journal of headache, 3331024241238153. https://doi.org/10.1177/03331024241238153 PMID: 38477313", "38477313" ], [ "Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, Giulia Fiorentini, Piero Barbanti (2024). Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence. Brain sciences. https://doi.org/10.3390/brainsci14090948 PMID: 39335442", "39335442" ], [ "Fatemeh Farham, Dilara Onan, Paolo Martelletti (2024). Non-Migraine Head Pain and Botulinum Toxin. Toxins. https://doi.org/10.3390/toxins16100431 PMID: 39453207", "39453207" ], [ "Dilara Onan, Fatemeh Farham, Paolo Martelletti (2024). Clinical Conditions Targeted by OnabotulinumtoxinA in Different Ways in Medicine. Toxins. https://doi.org/10.3390/toxins16070309 PMID: 39057949", "39057949" ] ] ], [ [ "JP", "Nasopharyngitis" ], 33.441371999999994 ], [ [ "fremanezumab", "Transformed migraine" ], 45.78865, [ [ "Patrick Eugeni, Megan E Rooney, Nicolas P Saikali, Zhongzheng Niu, Maurice T Driessen, Lynda J Krasenbaum, Karen Carr, Michael J Seminerio, Jennifer W McVige (2025). US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Advances in therapy. https://doi.org/10.1007/s12325-024-03063-w PMID: 39775579", "39775579" ], [ "Anna Maria Florescu, Lærke Vig Lannov, Samaira Younis, Christopher Kjaer Cullum, Basit Ali Chaudhry, Thien Phu Do, Faisal Mohammad Amin (2024). No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study. Cephalalgia : an international journal of headache, 3331024231222915. https://doi.org/10.1177/03331024231222915 PMID: 38215232", "38215232" ], [ "Cristina Tassorelli, Piero Barbanti, Cinzia Finocchi, Pierangelo Geppetti, Pinar Kokturk, Antonio Russo, Simona Sacco, Mario Cepparulo, (2024). The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2353-2363. https://doi.org/10.1007/s10072-024-07357-3 PMID: 38424386", "38424386" ], [ "Jason Charles Ray, Linda Dalic, Josephine Baker, Shuli Cheng, Elspeth Jane Hutton, Manjit Matharu (2024). Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study. BMJ neurology open, e000547. https://doi.org/10.1136/bmjno-2023-000547 PMID: 38268750", "38268750" ], [ "Takao Takeshima, Fumihiko Sakai, Xinyu Wang, Kentaro Yamato, Yoshitsugu Kojima, Yilong Zhang, Craig Bennison, Martijn J H G Simons (2024). Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective. PharmacoEconomics, 811-822. https://doi.org/10.1007/s40273-024-01380-0 PMID: 38771521", "38771521" ], [ "Shoji Kikui, Danno Daisuke, Junichi Miyahara, Hanako Sugiyama, Kuniko Ota, Kenji Murakata, Yoshihiro Kashiwaya, Takao Takeshima (2024). Effectiveness of fremanezumab treatment in patients with migraine headache. Pain medicine (Malden, Mass.), 664-670. https://doi.org/10.1093/pm/pnae050 PMID: 38889289", "38889289" ], [ "Sharon Wolters, Johannes A Carpay, Marja H Pronk, Karin W M Zuurbier, Maurice T Driessen, Leonidas Lyras, Maarten J Postma (2024). A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy. BMC neurology, 214. https://doi.org/10.1186/s12883-024-03697-x PMID: 38914929", "38914929" ], [ "Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, Mattia Canella, Marilena Marcosano, Claudia Altamura, Fabrizio Vernieri (2024). Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. The journal of headache and pain, 14. https://doi.org/10.1186/s10194-024-01721-6 PMID: 38308209", "38308209" ], [ "Emmanouil V Dermitzakis, Andreas A Argyriou, Konstantinos Bilias, Evangelia Barmpa, Sofia Liapi, Dimitrios Rikos, Georgia Xiromerisiou, Panagiotis Soldatos, Michail Vikelis (2024). Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options. Journal of clinical medicine. https://doi.org/10.3390/jcm13102768 PMID: 38792309", "38792309" ], [ "Muneto Tatsumoto, Miki Ishida, Katsuhiro Iba, Byung-Kun Kim, Xiaoping Ning, Chihiro Osawa, Masami Nakai, Yuka Kurita (2024). Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial. Headache. https://doi.org/10.1111/head.14810 PMID: 39221611", "39221611" ] ] ], [ [ "Receptors, Calcitonin Gene-Related Peptide", "Headache" ], 54.292656, [ [ "Sarah Stuart, Stephanie Gregg, Sally Ware, Prut Koonalintip, Benjamin R Wakerley (2024). Patient-completed online \"follow-up form\" to assess continuation of anti-CGRP(r) antibody therapy in patients with chronic migraine: A pilot project. Clinical neurology and neurosurgery, 108594. https://doi.org/10.1016/j.clineuro.2024.108594 PMID: 39481344", "39481344" ], [ "Darciane F Baggio, Eder Gambeta, Ivana A Souza, Sun Huang, Gerald W Zamponi, Juliana G Chichorro (2024). CaV3.2 T-type calcium channels contribute to CGRP- induced allodynia in a rodent model of experimental migraine. The journal of headache and pain, 219. https://doi.org/10.1186/s10194-024-01921-0 PMID: 39695919", "39695919" ], [ "Agustin Melo-Carrillo, Andrew M Strassman, Ron Broide, Aubrey Adams, Brett Dabruzzo, Mitchell Brin, Rami Burstein (2024). Novel insight into atogepant mechanisms of action in migraine prevention. Brain : a journal of neurology, 2884-2896. https://doi.org/10.1093/brain/awae062 PMID: 38411458", "38411458" ], [ "Ja Bin Hong, Heike Israel-Willner, Andreas Peikert, Peter Schanbacher, Viola Tozzi, Monika Köchling, Uwe Reuter, Bianca Raffaelli, (2024). Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies - insights from the German NeuroTransData registry. The journal of headache and pain, 90. https://doi.org/10.1186/s10194-024-01790-7 PMID: 38825722", "38825722" ], [ "Liwei Wang, Qing Wang, Huaqiong Diao, Xueying Liu, Yonglie Zhao (2024). The evolving landscape and research trend of calcitonin gene-related peptide in migraine: A bibliometric analysis and visualization. Frontiers in neurology, 1415760. https://doi.org/10.3389/fneur.2024.1415760 PMID: 38978815", "38978815" ], [ "Soohyun Cho, Byung-Kun Kim (2024). Long-Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine. Current pain and headache reports, 743-751. https://doi.org/10.1007/s11916-024-01259-x PMID: 38683278", "38683278" ], [ "William David Wells-Gatnik, Paolo Martelletti (2024). Switching CGRP(r) MoAbs in migraine: what evidence? Expert opinion on biological therapy, 327-333. https://doi.org/10.1080/14712598.2024.2354386 PMID: 38726800", "38726800" ], [ "Linda Sangalli, Bradley Eli, Sachi Mehrotra, Suzan Sabagh, James Fricton (2023). Calcitonin Gene-Related Peptide-Mediated Trigeminal Ganglionitis: The Biomolecular Link between Temporomandibular Disorders and Chronic Headaches. International journal of molecular sciences. https://doi.org/10.3390/ijms241512200 PMID: 37569575", "37569575" ], [ "Marcela Romero-Reyes, Gary Klasser, Simon Akerman (2023). An Update on Temporomandibular Disorders (TMDs) and Headache. Current neurology and neuroscience reports, 561-570. https://doi.org/10.1007/s11910-023-01291-1 PMID: 37581857", "37581857" ], [ "Birgit Vogler, Annette Kuhn, Kimberly D Mackenzie, Jennifer Stratton, Mária Dux, Karl Messlinger (2023). The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats. International journal of molecular sciences. https://doi.org/10.3390/ijms241713471 PMID: 37686275", "37686275" ] ] ], [ [ "Receptors, Calcitonin Gene-Related Peptide", "Migraine Disorders" ], 71.79271, [ [ "Aida Maddahi, Jacob C A Edvinsson, Lars Edvinsson (2024). Sex differences in expression of CGRP family of receptors and ligands in the rat trigeminal system. The journal of headache and pain, 193. https://doi.org/10.1186/s10194-024-01893-1 PMID: 39516766", "39516766" ], [ "Guy Greco, Teshamae Monteith (2024). Intranasal zavegepant for the acute treatment of migraine. Expert review of neurotherapeutics, 1131-1140. https://doi.org/10.1080/14737175.2024.2405741 PMID: 39314003", "39314003" ], [ "Irina Krikova, Kathleen B Digre, Bradley J Katz, Meagan D Seay, Judith E A Warner (2024). Migraine, idiopathic intracranial hypertension, and calcitonin gene-related peptide antibodies. Headache, 317-318. https://doi.org/10.1111/head.14686 PMID: 38477415", "38477415" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ], [ "Sawsan Alabbad, Nathalia Figueredo, Hsiangkuo Yuan, Stephen Silberstein (2024). Developments in targeting calcitonin gene-related peptide. Expert review of neurotherapeutics, 477-485. https://doi.org/10.1080/14737175.2024.2332754 PMID: 38557226", "38557226" ], [ "Messoud Ashina, Jan Hoffmann, Håkan Ashina, Debbie L Hay, Yadira Flores-Montanez, Thien Phu Do, Roberto De Icco, David W Dodick (2024). Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside. Mayo Clinic proceedings, 285-299. https://doi.org/10.1016/j.mayocp.2023.07.003 PMID: 38180396", "38180396" ], [ "Darciane F Baggio, Eder Gambeta, Ivana A Souza, Sun Huang, Gerald W Zamponi, Juliana G Chichorro (2024). CaV3.2 T-type calcium channels contribute to CGRP- induced allodynia in a rodent model of experimental migraine. The journal of headache and pain, 219. https://doi.org/10.1186/s10194-024-01921-0 PMID: 39695919", "39695919" ], [ "Eric Moore, Ian M Bell, Mark E Fraley, Christopher S Burgey, Rebecca B White, Chi-Chung Li, Christopher P Regan, Andrew Danziger, Steve P McGaraughty, Ghazal Naseri Kouzehgarani, Christopher Salvatore, Pradeep Banerjee (2024). Pharmacologic characterization of atogepant: A potent and selective calcitonin gene-related peptide receptor antagonist. Cephalalgia : an international journal of headache, 3331024231226186. https://doi.org/10.1177/03331024231226186 PMID: 38215228", "38215228" ], [ "Shafaqat M Rahman, Anne E Luebke (2024). Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models. Cephalalgia : an international journal of headache, 3331024231223971. https://doi.org/10.1177/03331024231223971 PMID: 38215227", "38215227" ], [ "Michel Lanteri-Minet, Shuu-Jiun Wang, Paolo Martelletti (2024). Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine. JAMA neurology. https://doi.org/10.1001/jamaneurol.2023.5835 PMID: 38407886", "38407886" ] ] ], [ [ "fremanezumab", "JP" ], 5.9883464 ], [ [ "fremanezumab", "Receptors, Calcitonin Gene-Related Peptide" ], 10.377924, [ [ "Patrick Eugeni, Megan E Rooney, Nicolas P Saikali, Zhongzheng Niu, Maurice T Driessen, Lynda J Krasenbaum, Karen Carr, Michael J Seminerio, Jennifer W McVige (2025). US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Advances in therapy. https://doi.org/10.1007/s12325-024-03063-w PMID: 39775579", "39775579" ], [ "Jessica Ailani, Anjana Lalla, Rashmi B Halker Singh, Dagny Holle-Lee, Krisztian Nagy, Kari Kelton, Cristiano Piron, Pranav Gandhi, Patricia Pozo-Rosich (2024). Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies. Cephalalgia : an international journal of headache, 3331024241299377. https://doi.org/10.1177/03331024241299377 PMID: 39558612", "39558612" ], [ "Anjaneya Shankar Madhav Bandatmakur, Pooja Dave, Melissa Kerr, Colin Brunick, Sijin Wen, Nicholas Hansen (2024). Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA. Brain sciences. https://doi.org/10.3390/brainsci14090879 PMID: 39335375", "39335375" ], [ "Reem Suliman, Vanessa Santos, Ibrahim Al Qaisi, Batool Aldaher, Ahmed Al Fardan, Hajir Al Barrawy, Yazan Bader, Jonna Lyn Supena, Kathrina Alejandro, Taoufik Alsaadi (2024). Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study. Neurology international, 274-288. https://doi.org/10.3390/neurolint16010019 PMID: 38392960", "38392960" ], [ "Paul Triller, Virginia N Blessing, Lucas H Overeem, Mira P Fitzek, Ja Bin Hong, Kristin S Lange, Uwe Reuter, Bianca Raffaelli (2024). Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study. Cephalalgia : an international journal of headache, 3331024241288875. https://doi.org/10.1177/03331024241288875 PMID: 39469839", "39469839" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ], [ "Edoardo Caronna, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich (2024). CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. Handbook of clinical neurology, 107-124. https://doi.org/10.1016/B978-0-12-823357-3.00024-0 PMID: 38307640", "38307640" ], [ "Miguel Ruiz, Alexandra Cocores, Antonella Tosti, Peter J Goadsby, Teshamae S Monteith (2023). Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review. Cephalalgia : an international journal of headache, 3331024221143538. https://doi.org/10.1177/03331024221143538 PMID: 36739513", "36739513" ], [ "Sandhya Jinesh (2023). Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine. Inflammopharmacology, 2245-2251. https://doi.org/10.1007/s10787-023-01276-z PMID: 37421480", "37421480" ], [ "Katina Aleksovska, Andrew D Hershey, Marie Deen, Robert de Icco, Mi Ji Lee, Hans-Christoph Diener (2023). Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society. Cephalalgia : an international journal of headache, 3331024231206162. https://doi.org/10.1177/03331024231206162 PMID: 37879637", "37879637" ] ] ], [ [ "Botulinum Toxins, Type A", "Overactive Bladder" ], 10.341675, [ [ "(2024). Aktuelle Urologie, 21. https://doi.org/10.1055/a-2056-2793 PMID: 38330951", "38330951" ], [ "Yuan-Hong Jiang, Jia-Fong Jhang, Sheng-Fu Chen, Hann-Chorng Kuo (2024). Real-Life Treatment Outcome of Botulinum Toxin A Injection on Overactive Bladder and Voiding Dysfunction in Patients with Central Nervous System Lesions. Toxins. https://doi.org/10.3390/toxins16030123 PMID: 38535789", "38535789" ], [ "Alain Ruffion, Pierre Karam, Anne Forestier, Pierre Denys (2024). Real-World Use of Intradetrusor Botulinum Toxin Injections: A Population-Based Study from France. Toxins. https://doi.org/10.3390/toxins16100423 PMID: 39453198", "39453198" ], [ "Grace Forde, Benjamin M Brucker, Kimberly Becker Ifantides, Atul T Patel, Angeli Mayadev, Theodore Brown, Ziyad Ayyoub, Kenneth Martinez, Ritu Singh, Mariana Nelson, Simona Battucci, Irina Yushmanova, Ahunna Ukah, Christopher Rhyne (2024). SYNCHRONIZE: Real-World Retrospective Safety Analysis of Patients Treated with OnabotulinumtoxinA for More than One Therapeutic Indication. Toxins. https://doi.org/10.3390/toxins16100420 PMID: 39453196", "39453196" ], [ "Andrea Panunzio, Rossella Orlando, Giovanni Mazzucato, Sonia Costantino, Giulia Marafioti Patuzzo, Clara Cerrato, Rita De Mitri, Vincenzo Pagliarulo, Alessandro Tafuri, Antonio Benito Porcaro, Alessandro Antonelli, Riccardo Giuseppe Bertolo, Luca Giacomello, Maria Angela Cerruto (2024). Response to Treatment with Botulinum Neurotoxin A (BoNT-A) in Children and Adolescents with Neurogenic Lower Urinary Tract Dysfunction and Idiopathic Overactive Bladder: A Systematic Review and Meta-Analysis. Toxins. https://doi.org/10.3390/toxins16100443 PMID: 39453219", "39453219" ], [ "Leslie M Peard, John C Pope, Roger Dmochowski (2023). An evaluation of onobotulinumtoxinA as a therapeutic option for pediatric neurogenic detrusor overactivity. Expert review of neurotherapeutics, 763-774. https://doi.org/10.1080/14737175.2023.2246661 PMID: 37556757", "37556757" ], [ "Pierre Denys, Juan Carlos Castaño Botero, Ricardo Luis Vita Nunes, Barton Wachs, Cristiano Mendes Gomes, Grigory Krivoborodov, Le Mai Tu, Giulio Del-Popolo, Catherine Thompson, Claire Vilain, Magali Volteau, Michael Kennelly, (2023). AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2). Neurourology and urodynamics, 153-167. https://doi.org/10.1002/nau.25062 PMID: 36321799", "36321799" ], [ "Djamel Bensmail, Pierre Karam, Anne Forestier, Jean-Yves Loze, Jonathan Lévy (2023). Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study. Toxins. https://doi.org/10.3390/toxins15040280 PMID: 37104218", "37104218" ], [ "Luis Ribeiro, Lap Yan Leung, Nataniel Tan, Zhi-Yang Low, Mathura Nagarajah, Ghazia Ahmed, Mikaela Carey, Samer Sabbagh, Davendra Sharma, Jai Seth (2023). Predictors for adverse events following intravesical botulinum toxin injections in men. Neurourology and urodynamics, 1499-1505. https://doi.org/10.1002/nau.25230 PMID: 37386824", "37386824" ], [ "Mitchell M Huang, Nicholas S Dean, Mark A Assmus, Matthew S Lee, Jenny N Guo, Amy E Krambeck (2023). Intradetrusor OnabotulinumtoxinA Injections at the Time of Holmium Laser Enucleation of the Prostate for Men with Severe Storage Symptoms. Journal of endourology, 801-806. https://doi.org/10.1089/end.2023.0074 PMID: 37053094", "37053094" ] ] ], [ [ "calcitonin gene-related peptide", "Transformed migraine" ], 21.127892999999997, [ [ "Yao Zhang, Fei Ge, Yamin Luo, Xuenian Ji, Zijian Liu, Yuehua Qiu, Jianchen Hou, Ranran Zhou, Caihong Zhao, Qianwei Xu, Shujing Zhang, Xue Yu, Chunguo Wang, Dongyu Ge, Fengxian Meng, Xiaohua Tao (2024). Paeonol and glycyrrhizic acid in combination ameliorate the recurrent nitroglycerin-induced migraine-like phenotype in rats by regulating the GABBR2/TRPM8/PRKACA/TRPV1 pathway. Journal of ethnopharmacology, 118464. https://doi.org/10.1016/j.jep.2024.118464 PMID: 38908492", "38908492" ], [ "Tianxiao Wang, Chenlu Zhu, Kaibo Zhang, Jinggui Gao, Yunhao Xu, Chenyang Duan, Shouyi Wu, Cheng Peng, Jisong Guan, Yonggang Wang (2024). Targeting IGF1/IGF1r signaling relieve pain and autophagic dysfunction in NTG-induced chronic migraine model of mice. The journal of headache and pain, 156. https://doi.org/10.1186/s10194-024-01864-6 PMID: 39304806", "39304806" ], [ "Marta Pascual-Mato, Gabriel Gárate, Vicente González-Quintanilla, Jorge Madera-Fernández, Beatriz Castro, María José García, Javier Crespo, Montserrat Rivero, Julio Pascual (2024). Differences in circulating alpha-calcitonin gene-related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross-sectional study. Headache, 849-858. https://doi.org/10.1111/head.14768 PMID: 38922858", "38922858" ], [ "Lanfranco Pellesi, Dilara Onan, Paolo Martelletti (2024). Onabotulinumtoxin A for the Treatment of Post-Traumatic Headache: Is It Better than Anti-CGRP Antibodies? Toxins. https://doi.org/10.3390/toxins16100427 PMID: 39453203", "39453203" ], [ "Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia : an international journal of headache, 3331024241238153. https://doi.org/10.1177/03331024241238153 PMID: 38477313", "38477313" ], [ "Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, Giulia Fiorentini, Piero Barbanti (2024). Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence. Brain sciences. https://doi.org/10.3390/brainsci14090948 PMID: 39335442", "39335442" ], [ "Ana Beatriz Gago-Veiga, Noelia Lopez-Alcaide, Sonia Quintas, Iris Fernández Lázaro, Javier Casas-Limón, Carlos Calle, Germán Latorre, Nuria González-García, Jesús Porta-Etessam, Jaime Rodriguez-Vico, Alex Jaimes, Andrea Gómez García, David García-Azorín, Ángel Luis Guerrero-Peral, Álvaro Sierra, Alberto Lozano Ros, Antonio Sánchez-Soblechero, Javier Díaz-de-Teran, Javier A Membrilla, Cristina Treviño, Alicia Gonzalez-Martinez (2024). Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC study. European journal of neurology, e16215. https://doi.org/10.1111/ene.16215 PMID: 38323742", "38323742" ], [ "Matthew Robbins (2024). New Daily Persistent Headache. Continuum (Minneapolis, Minn.), 425-437. https://doi.org/10.1212/CON.0000000000001398 PMID: 38568492", "38568492" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ], [ "Sawsan Alabbad, Nathalia Figueredo, Hsiangkuo Yuan, Stephen Silberstein (2024). Developments in targeting calcitonin gene-related peptide. Expert review of neurotherapeutics, 477-485. https://doi.org/10.1080/14737175.2024.2332754 PMID: 38557226", "38557226" ] ] ], [ [ "CGRP", "Migraine Disorders" ], 61.064243, [ [ "Sajjad Jabbari, Zainul Amiruddin Zakaria, Irwin Rose Alencar de Menezes, Saeed Mohammadi (2025). Antinociceptive, antineuropathic, and antimigraine-like activities ofFritillariaimperialis L. rich in verticinone on rats: Mechanisms of action. Journal of ethnopharmacology, 119174. https://doi.org/10.1016/j.jep.2024.119174 PMID: 39613005", "39613005" ], [ "Lauren Powell, Fiona O'Sullivan, Pramoda Jayasinghe, Basia Rogula, Feng Dai, Jessica Cirillo, Samantha Sweeney, Lucy Abraham, Jessica Ailani (2025). Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial. The journal of headache and pain, 1. https://doi.org/10.1186/s10194-024-01915-y PMID: 39748312", "39748312" ], [ "Davide Para, Chiara Camponovo, Gianna Carla Riccitelli, Giulia Mallucci, Paolo Maino, Camilla Mondini Trissino da Lodi, Demurtas Saudina, Pierpaolo Trimboli, Claudio Gobbi, Chiara Zecca (2024). Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies. CNS drugs, 819-825. https://doi.org/10.1007/s40263-024-01104-0 PMID: 39174745", "39174745" ], [ "Yao Zhang, Fei Ge, Yamin Luo, Xuenian Ji, Zijian Liu, Yuehua Qiu, Jianchen Hou, Ranran Zhou, Caihong Zhao, Qianwei Xu, Shujing Zhang, Xue Yu, Chunguo Wang, Dongyu Ge, Fengxian Meng, Xiaohua Tao (2024). Paeonol and glycyrrhizic acid in combination ameliorate the recurrent nitroglycerin-induced migraine-like phenotype in rats by regulating the GABBR2/TRPM8/PRKACA/TRPV1 pathway. Journal of ethnopharmacology, 118464. https://doi.org/10.1016/j.jep.2024.118464 PMID: 38908492", "38908492" ], [ "E Pons-Fuster, O Lozano-Caballero, S Martín-Balbuena, C Lucas-Ródenas, A Mancebo-González, I De Gorostiza-Frías, C M González-Ponce (2024). Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. International journal of clinical pharmacy, 1317-1326. https://doi.org/10.1007/s11096-024-01758-2 PMID: 38990457", "38990457" ], [ "Richard B Lipton, Stephanie J Nahas, Patricia Pozo-Rosich, Tanya Bilchik, Peter McAllister, Michelle Finnegan, Yingyi Liu, Natty Chalermpalanupap, Brett Dabruzzo, David W Dodick (2024). Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. The journal of headache and pain, 83. https://doi.org/10.1186/s10194-024-01783-6 PMID: 38773375", "38773375" ], [ "Lanfranco Pellesi, Dilara Onan, Paolo Martelletti (2024). Onabotulinumtoxin A for the Treatment of Post-Traumatic Headache: Is It Better than Anti-CGRP Antibodies? Toxins. https://doi.org/10.3390/toxins16100427 PMID: 39453203", "39453203" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ], [ "Katherine Phillips, Benjamin R Wakerley (2024). CGRP therapy in primary care for migraine: prevention and acute medication. The British journal of general practice : the journal of the Royal College of General Practitioners, 521-522. https://doi.org/10.3399/bjgp24X739893 PMID: 39481905", "39481905" ], [ "Nazia Karsan, Lars Edvinsson, Laszlo Vecsei, Peter J Goadsby (2024). Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders. Annals of clinical and translational neurology, 1654-1668. https://doi.org/10.1002/acn3.52119 PMID: 38887982", "38887982" ] ] ], [ [ "JP", "Headache" ], 32.09053, [ [ "Muhammad Hamza Dawood, Shanila Feroz, Sheza Sohail, Mavra Roshan, Haseefa Perveen, Tasmiha Nizam (2024). Efficacy of 0.1% Xylometazoline-Hydrochloride Nasal Decongestant Spray in Postoperative Sign/Symptom Relief Following Septoplasty: A Randomized Control Trial. Ear, nose, & throat journal, 1455613241266473. https://doi.org/10.1177/01455613241266473 PMID: 39076161", "39076161" ], [ "Ubiratan Cardinalli Adler, Maristela Schiabel Adler, Livia Mitchiguian Hotta, Ana Elisa Madureira Padula, Amarilys de Toledo Cesar, José Nelson Martins Diniz, Crislaine Aparecida Antonio Mestre, Katia Regina Spiller, Lidiamara Soares, Helen de Freitas Santos, Edson Zangiacomi Martinez (2021). Homeopathy for Covid-19 in Primary Care: A structured summary of a study protocol for a randomized controlled trial. Trials, 109. https://doi.org/10.1186/s13063-021-05071-5 PMID: 33522951", "33522951" ], [ "Reiko Kishi, Hiroshi Yoshino, Atsuko Araki, Yasuaki Saijo, Kenichi Azuma, Toshio Kawai, Hiroshi Yamato, Haruki Osawa, Eiji Shibata, Masatoshi Tanaka, Ayumi Masuchi, Machiko Minatoya, Yu Ait Bamai (2018). [New Scientific Evidence-based Public Health Guidelines and Practical Manual for Prevention of Sick House Syndrome]. Nihon eiseigaku zasshi. Japanese journal of hygiene, 116-129. https://doi.org/10.1265/jjh.73.116 PMID: 29848862", "29848862" ] ] ] ] }